Home Newsfeeds Morgan Stanley Maintains Overweight on Advanced Micro Devices, Raises Price Target to $87

Morgan Stanley Maintains Overweight on Advanced Micro Devices, Raises Price Target to $87

Morgan Stanley analyst Joseph Moore maintains Advanced Micro Devices (NASDAQ:AMD) with a Overweight and raises the price target from $77 to $87.

byBenzinga Newsdesk

February 1, 2023

1 minute read

Morgan Stanley analyst Joseph Moore maintains Advanced Micro Devices (NASDAQ:AMD) with a Overweight and raises the price target from $77 to $87.

PetVivo Reports FY23 Full Year Financial Results; FY23 EPS $(0.85) Vs $(0.57) YoY; Revenue $917,162 Vs $115,586 YoY

By Happy Mohamed

June 29, 3:48 PM

For The Fiscal Year Ended March 31, 2023 Compared to The Fiscal Year Ended March 31, 2022 Total Revenues. Revenues were $917,162 in fiscal 2023 compared

PETV

Stellantis Acquires 33% Stake In Hydrogen Mobility Firm Symbio

By Shivani Kumaresan

May 16, 7:58 AM

Stellantis NV (NYSE:STLA) has signed a binding agreement to acquire a 33.3% stake in Symbio, a zero-emission hydrogen mobility company.…

MGDDY

Radiology Imaging Associates Launches The Enhanced Breast Cancer Detection Program, Providing Women A New State-Of-The-Art Solution Powered By Artificial Intelligence

By Happy Mohamed

February 6, 9:48 AM

Radiology Imaging Associates, a division of RadNet, Inc. (NASDAQ:RDNT), today announced that it has started implementation of its new Enhanced Breast Cancer Detection (EBCD) service (https://myEBCDmammo.com), which works

RDNT

News

Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper

By Benzinga Newsdesk

May 24, 3:20 AM

Mainz Biomed NV (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today initial results from its

MYNZ

Morgan Stanley Maintains Overweight on Advanced Micro Devices, Raises Price Target to $87

Related Posts

PetVivo Reports FY23 Full Year Financial Results; FY23 EPS $(0.85) Vs $(0.57) YoY; Revenue $917,162 Vs $115,586 YoY

Stellantis Acquires 33% Stake In Hydrogen Mobility Firm Symbio

Radiology Imaging Associates Launches The Enhanced Breast Cancer Detection Program, Providing Women A New State-Of-The-Art Solution Powered By Artificial Intelligence

Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper